Drug Landscape ›
TRIPTORELIN ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 1,659
Most-reported reactions
Off Label Use — 310 reports (18.69%) Death — 302 reports (18.2%) Ovarian Hyperstimulation Syndrome — 240 reports (14.47%) Disease Progression — 193 reports (11.63%) Asthenia — 107 reports (6.45%) Dementia Alzheimer^S Type — 106 reports (6.39%) Malignant Neoplasm Progression — 106 reports (6.39%) Anaemia — 105 reports (6.33%) Fatigue — 96 reports (5.79%) Nausea — 94 reports (5.67%)
Source database →
TRIPTORELIN in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is TRIPTORELIN approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for TRIPTORELIN in United States?
Marketing authorisation holder not available in our data.